loading page

Identification of a plant-derived small molecule with potent anti-obesity and anti-diabetic activities in type 2 diabetic mice
  • +10
  • yao Wang,
  • Jing Luo,
  • Aiping wang,
  • Yajun Wu,
  • Aihua Wang,
  • Hana Alkhalidy,
  • Richard Helm,
  • Hongguang Ma,
  • Yan Zhang,
  • Jennifer Rainville,
  • Georgia Hodes ,
  • Bin Xu,
  • Dongmin Liu
yao Wang
Virginia Tech

Corresponding Author:yaow@vt.edu

Author Profile
Jing Luo
Sun Yat-Sen University
Author Profile
Aiping wang
Zhengzhou University
Author Profile
Yajun Wu
Virginia Tech
Author Profile
Aihua Wang
Virginia Tech
Author Profile
Hana Alkhalidy
Jordan University of Science and Technology
Author Profile
Richard Helm
Virginia Tech
Author Profile
Hongguang Ma
Virginia Commonwealth University
Author Profile
Yan Zhang
Virginia Commonwealth University
Author Profile
Jennifer Rainville
Virginia Tech
Author Profile
Georgia Hodes
Virginia Tech
Author Profile
Bin Xu
North Carolina Central University
Author Profile
Dongmin Liu
Virginia Tech
Author Profile

Abstract

Insulin resistance and progressive decline in functional β-cell mass are two key factors for developing T2D, which is largely driven by overweight and obesity, a significant obstacle for effective metabolic control in many patients with T2D. Thus, agents that simultaneously ameliorate obesity and promote insulin sensitivity and β-cell function could be more effective for treating T2D. Here, we report that elenolic acid (EA), a small molecule, is such a dual-action agent. Oral administration of EA restored glucose homeostasis and other metabolic disorders in diet-induced obese mice, which were associated with increased circulating GLP-1, PYY, and GIP concentrations. EA slowed gastric emptying, downregulated hypothalamic agouti-related peptide, and reduced food intake and obesity in obese mice. EA also exerted potent anti-hyperglycemic effect in db/db mice that was comparable to that of liraglutide but greater than that of metformin, and it was more effective in promoting weight loss relative to these two drugs. Mechanistically, EA directly stimulated GLP-1 and PYY secretion from L-cells, and its induction of GLP-1 release is mediated via Gαq/phospholipase C-mediated pathway. EA also directly suppresses glucose production in liver cells. These results suggest that EA is a novel, dual-action agent for developing drug to treat both T2D and obesity.